Clinical Trial Update: Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria [Phase 3]

View source ↗

Summary

Phase 3 trial update for BCD-148 and Soliris in paroxysmal nocturnal hemoglobinuria (PNH) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• BCD-148
• SOLIRIS (eculizumab)

Snippet

Sponsor: Biocad | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: COMPLETED